| Sep 1, 2025 | Nutrium | $12.0M Series A | Qasim Al-Zawawi | Indico Capital Partners, Portugal Ventures, Beta Capital, Lince Capital |
| Jul 10, 2024 | HepaRegeniX | $16.2M Series C | Vesalius Biocapital | — |
| May 1, 2024 | Memo Therapeutics | $22.0M Series C | — | Kurma Partners, Adjuvant Capital, Fresenius Medical Care Ventures, GF Group, Pureos Bioventures, Redalpine, Schroders Capital, Swisscanto Invest, Verve Ventures, Thomas Harth |
| Mar 1, 2024 | Tonic App | $12.0M Series A | António Mello Campello, João Henriques | Armilar Venture Partners, Telegraph Hill Partners, François Sarkozy, Teresa Fiúza, Shilling |
| Nov 1, 2023 | Memo Therapeutics | $28.0M Series C | Veronica Gambillara Fonck | Adjuvant Capital, Kurma Partners, Pureos Bioventures, Fresenius Medical Care Ventures, GF Group, Redalpine, Schroders Capital, Swisscanto Invest, Verve Ventures |
| Mar 11, 2022 | Scenic Biotech | $31.0M Series A | Michael Wacker, Stephan Christgau, Stephane Verdood | BioGeneration Ventures, INKEF Capital, Oxford Science Enterprises |
| Feb 1, 2022 | Memo Therapeutics | $25.0M Series B | Swisscanto Invest, Swiss Federal Office of Public Health | Adjuvant Capital, Kurma Partners, Pureos Bioventures, Andreas Wüpper, GF Group, Verve Ventures, Christian Schneider, Zürcher Kantonalbank |
| Oct 12, 2021 | Rejuvenate Biomed | $18.2M Series B | Rejuveron Life Sciences, Vesalius Biocapital | — |
| Jul 29, 2021 | Topas Therapeutics | $21.3M Series B Extension | — | BioMedPartners, Boehringer Ingelheim, EMBL Ventures, Epidarex Capital, Werner Lanthaler, Gimv |
| Jan 1, 2021 | Sword Health | $25.0M Series B | — | Acrew Capital, AllegisCyber Capital, Alumni Ventures, Earthshot Ventures, Energy Impact Partners, Highland Capital Partners, Insight Partners, Khosla Ventures, Owl Capital, Reach Capital, Rethink Impact, The Westly Group, Transformation Capital, Julius Genachowski, Louis Beryl, Siqi Chen, Faber Ventures, Founders Fund, Green Innovations |
| Nov 10, 2020 | CatalYm | $59.1M Series B | Vesalius Biocapital | — |
| Oct 19, 2020 | Topas Therapeutics | $25.9M Series B | Michael Wacker, Marc Lohrmann | — |
| Feb 14, 2020 | OncoDNA | $20.6M Series B | Robert Schier, Guy Geldhof | CPH Bank, Inventures, Sambrinvest, Fontaine François, Sofinim, SRIW |
| Feb 1, 2020 | Sword Health | $9.0M Series A | Khosla Ventures | LGF, Owl Capital, Reach Capital, Rethink Impact, Siqi Chen, Lachy Groom, Faber Ventures, Delian Asparouhov, Green Innovations |
| Jan 14, 2020 | Mecuris | $4.0M Other Equity | — | Bayern Kapital, High-Tech Grunderfonds, Mulcan International Investments, Sana Kliniken |
| Dec 13, 2019 | Tonic App | $3.9M Other Equity | Armilar Venture Partners, Vesalius Biocapital | — |
| Jul 22, 2019 | DEARhealth | $6.7M Series A | — | Dick Sietses, Lara Koole, Marc Lohrmann |
| Nov 1, 2018 | OMEICOS Therapeutics | $19.0M Series C | Forbion | High-Tech Gründerfonds, High-Tech Grunderfonds, IBB Ventures, KfW, Remiges Ventures, SMS Group, The Falck Revocable Trust, Christian Schneider |
| Apr 16, 2018 | Sword Health | $4.6M Seed | — | Green Innovations |
| Nov 17, 2017 | Ncardia | $12.4M Series B | Marc Foidart | InnovationQuarter, Sambrinvest, SFPI-FPIM, SRIW |
| Mar 1, 2017 | OMEICOS Therapeutics GmbH | $8.8M Series B | SMS Group, Christian Schneider | Ascension Ventures, High-Tech Grunderfonds, IBB Ventures, KfW, The Falck Revocable Trust |
| Jan 5, 2017 | Exact Imaging | $16.3M Series C | Peter van der Velden, MBA, M.Sc., Gaston Matthyssens | Sam Ifergan, Alexandra Tolia |
| Oct 28, 2016 | Promethera Biosciences | $10.9M Series C Extension | — | Boehringer Ingelheim, Cell Innovation Partners, Fund+, LifeLiver, Muneki Handa, SMS Investments, SRIW |
| Oct 2, 2015 | Euroscreen | $18.0M Series B | Fund+, SFPI-FPIM | BNP Paribas Fortis Private Equity, Capricorn Venture Partners, SRIW |
| Sep 29, 2015 | Apitope | $13.5M Series B | Brenig Preest | LRM, PMV, Wyvern |
